Welcome to resTORbio

resTORbio, Inc. is a clinical-stage biopharmaceutical company developing innovative medicines that target the biology of aging to prevent or treat aging-related diseases.

Our lead program selectively inhibits the target of rapamycin complex 1, or TORC1, an evolutionarily conserved pathway that contributes to the decline in function of multiple organ systems as people age, including immune, neurologic, and cardiac function. Our lead product candidate, RTB101, is an oral, selective, and potent TORC1 inhibitor. TORC1 inhibition has been shown to benefit multiple aging-related conditions in preclinical studies, including immunosenescence, which is the decline of a body’s immune system during aging. In two Phase 2 clinical trials that enrolled more than 900 people 65 years and older, RTB101 was observed to improve immune function and reduce the incidence of illness associated with respiratory tract infections, or RTIs. Based on these Phase 2 data, in May 2019, resTORbio initiated our global Phase 3 PROTECTOR program to evaluate the safety and efficacy of RTB101 for reducing the percent of people age 65 and older with clinically symptomatic respiratory illness. 

 
 

resTORbio’s goal is to be a leading pharmaceutical company focused
on treating aging-related diseases.

 

Our Team

 
Chen_Schor.png

Chen Schor
Co-Founder, President and CEO

 
Abdellah.png

Abdellah Sentissi, Ph.D
Head of CMC and Pharmaceutical Development (Contractor)

Joan_Mannick.png

Joan Mannick, M.D.
Co-Founder, Chief Medical Officer

 
Karen-Jauregui.png

Karen Jauregui
Vice President of Regulatory Affairs

 
Meredith_Manning.png

Meredith Manning
Chief Commercial Officer

Sarb_Shergill.png

Sarb Shergill, Ph.D.
Vice President of Clinical Operations

 
John_McCabe.png

John McCabe
Vice President of Finance

 
Chen_Schor.png

Chen Schor
Board of Directors

 
Michael_Grissinger.png

Michael Grissinger
Board of Directors

 
Jeff_Chodakewitz.png
Jonathan-Silverstein.png

Jonathan Silverstein, J.D.
Board of Directors

 
David_Steinburg.png

David Steinberg
Board of Directors

Paul-Fonteyne.png

Paul Fonteyne
Board of Directors

 
LynneSullivan.png

Lynne Sullivan
Board of Directors

 
Hayden-8.png

Frederick G. Hayden, M.D.
Clinical Advisory Board Member

Johnston-8.png

Sebastian L. Johnston, Ph.D.
Clinical Advisory Board Member

 
Whitley-8.png

Richard Whitley, M.D.
Clinical Advisory Board Member

McElhaney-8.png

Janet McElhaney, M.D.
Clinical Advisory Board Member